Employees: 316
Size IVF HARTMANN (VBSN.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $352M, the 149th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 125.00 on 18 Nov 2026.
Performance Over six months the shares fell 2.0%, against -18.1% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue grew 6.9% over the last twelve months (peer median +2.2%); the operating margin is 14.0% (peer median 6.4%).
Valuation It trades at 1.1× enterprise value to sales against a peer median of 4.6× (2nd cheapest of 21).
Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 31.4 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 170M | CHF 162M | CHF 159M | CHF 148M | CHF 151M |
| Revenue growth | — | +2% | +7% | -2% | — |
| Gross profit | CHF 55.4M | CHF 52.9M | CHF 54.1M | CHF 45.0M | CHF 43.9M |
| EBITDA | CHF 28.6M | CHF 21.8M | CHF 24.7M | CHF 17.6M | CHF 16.1M |
| Net income | CHF 20.3M | CHF 18.3M | CHF 20.3M | CHF 15.1M | CHF 11.2M |
| Free cash flow | CHF 23.3M | CHF 17.7M | CHF 18.2M | CHF 31.8M | CHF 15.5M |
| Capital expenditure | CHF 3.36M | CHF 3.97M | CHF 2.58M | CHF 2.42M | CHF 2.71M |
| Total debt | n/a | CHF 1.39M | CHF 1.30M | CHF 1.34M | CHF 931,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VBSN.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.8% | -10.9% | 4th highest of 21 |
| 6-month return | -2.0% | -18.1% | 6th highest of 20 |
| Distance from 52-week high | -16.7% | -47.5% | 3rd highest of 21 |
| Revenue growth (TTM) | +6.9% | +2.2% | 10th highest of 21 |
| Operating margin | 14.0% | 6.4% | 7th highest of 21 |
| EV / Sales | 1.1× | 4.6× | 2nd cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | -12.7% | 16.4% | 4th least demanding of 15 |
| Growth delivered (Del g) | -1.3% | +0.2% | 5th lowest of 15 |
| Hurdle (Req g minus delivered) | -11.4 pp | +9.8 pp | 3rd least demanding of 15 |
| ROIC minus cost of capital | +31.4 pp | -3.3 pp | 2nd highest of 19 |
| EV / EBITDA | 6.8× | 11.9× | 3rd cheapest of 11 |
| Net debt / EBITDA | -3.6× | 0.4× | 5th least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| IVF HARTMANN VBSN.SW | Switzerland | $352M | -2% | +7% | 14% | 1.1× | -12.7% | -1.3% |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $354M | -23% | -8% | 17% | 5.4× | 18.4% | +4.4% |
| Embecta EMBC | United States | $345M | +99% | -8% | 26% | 1.6× | -19.9% | -0.1% |
| YD Bio YDES | United States | $344M | +7% | +17% | -883% | 571.2× | n/a | n/a |
| Beijing Succeeder Technology 688338.SS | China | $362M | -18% | -4% | 31% | 4.2× | 5.7% | +3.4% |
| Star Sports Medicine 1609.HK | Hong Kong | $364M | -73% | +23% | 37% | 3.7× | -13.1% | +36.8% |
| Stratec SBS.DE | Germany | $365M | +63% | -6% | 4% | 1.8× | 19.1% | +0.1% |
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | 24.8× | n/a | n/a |
| COLTENE CLTN.SW | Switzerland | $339M | -7% | -2% | 8% | 1.4× | -0.3% | -0.7% |
| Nanjing Medlander Medical Technology 688273.SS | China | $337M | -47% | -12% | 8% | 4.2× | 35.3% | +5.2% |
| BioNote 377740.KS | South Korea | $337M | -14% | +12% | 18% | 1.0× | -15.0% | -28.5% |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $336M | -36% | -5% | 2% | 4.9× | 34.3% | +0.4% |
| Brainsway Ltd Sponsored ADR BWAY | United States | $373M | -41% | +32% | 14% | 4.8× | 24.9% | +18.8% |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $373M | -15% | +7% | 11% | 1.8× | -4.2% | -6.0% |
| ACRO Biomedical 6748.TWO | Taiwan | $377M | +158% | +45% | -178% | 218.3× | n/a | n/a |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $378M | n/a | +19% | 2% | 1.5× | 17.1% | +18.1% |
| Tauns Laboratories 197A.T | Japan | $327M | -3% | +7% | 29% | 4.4× | n/a | n/a |
| Chemclin Diagnostics 688468.SS | China | $327M | -24% | -10% | 4% | 6.4× | 15.8% | -4.5% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $379M | -26% | -11% | 5% | 7.8× | n/a | n/a |
| Jiangsu Apon Medical Technology 300753.SZ | China | $326M | -34% | -15% | -10% | 6.9× | 20.0% | -5.1% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $326M | -27% | +12% | -2% | 7.4× | n/a | n/a |